These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 29295564)

  • 1. Mesoporous Silica Nanoparticles for Drug Delivery: Current Insights.
    Vallet-Regí M; Colilla M; Izquierdo-Barba I; Manzano M
    Molecules; 2017 Dec; 23(1):. PubMed ID: 29295564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lectin-conjugated pH-responsive mesoporous silica nanoparticles for targeted bone cancer treatment.
    Martínez-Carmona M; Lozano D; Colilla M; Vallet-Regí M
    Acta Biomater; 2018 Jan; 65():393-404. PubMed ID: 29127069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery.
    Baeza A; Colilla M; Vallet-Regí M
    Expert Opin Drug Deliv; 2015 Feb; 12(2):319-37. PubMed ID: 25421898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesoporous Silica and Organosilica Nanoparticles: Physical Chemistry, Biosafety, Delivery Strategies, and Biomedical Applications.
    Croissant JG; Fatieiev Y; Almalik A; Khashab NM
    Adv Healthc Mater; 2018 Feb; 7(4):. PubMed ID: 29193848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery: an update.
    Castillo RR; Lozano D; González B; Manzano M; Izquierdo-Barba I; Vallet-Regí M
    Expert Opin Drug Deliv; 2019 Apr; 16(4):415-439. PubMed ID: 30897978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in Peptide Functionalization on Mesoporous Silica Nanoparticles for Controlled Drug Release.
    Hu JJ; Xiao D; Zhang XZ
    Small; 2016 Jul; 12(25):3344-59. PubMed ID: 27152737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesoporous silica nanoparticles in nanomedicine applications.
    Manzano M; Vallet-Regí M
    J Mater Sci Mater Med; 2018 May; 29(5):65. PubMed ID: 29737405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomedical application of mesoporous silica nanoparticles as delivery systems: a biological safety perspective.
    Hosseinpour S; Walsh LJ; Xu C
    J Mater Chem B; 2020 Nov; 8(43):9863-9876. PubMed ID: 33047764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The practicality of mesoporous silica nanoparticles as drug delivery devices and progress toward this goal.
    Roggers R; Kanvinde S; Boonsith S; Oupický D
    AAPS PharmSciTech; 2014 Oct; 15(5):1163-71. PubMed ID: 24871552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multimodal Mesoporous Silica Nanocarriers for Dual Stimuli-Responsive Drug Release and Excellent Photothermal Ablation of Cancer Cells.
    Tran VA; Vo VG; Shim K; Lee SW; An SSA
    Int J Nanomedicine; 2020; 15():7667-7685. PubMed ID: 33116494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesoporous silica nanoparticle nanocarriers: biofunctionality and biocompatibility.
    Tarn D; Ashley CE; Xue M; Carnes EC; Zink JI; Brinker CJ
    Acc Chem Res; 2013 Mar; 46(3):792-801. PubMed ID: 23387478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The viability of mesoporous silica nanoparticles for drug delivery.
    Zhang J; Rosenholm JM
    Ther Deliv; 2015; 6(8):891-3. PubMed ID: 26271998
    [No Abstract]   [Full Text] [Related]  

  • 13. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers.
    Slowing II; Vivero-Escoto JL; Wu CW; Lin VS
    Adv Drug Deliv Rev; 2008 Aug; 60(11):1278-1288. PubMed ID: 18514969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesoporous silica nanoparticles for stimuli-responsive controlled drug delivery: advances, challenges, and outlook.
    Song Y; Li Y; Xu Q; Liu Z
    Int J Nanomedicine; 2017; 12():87-110. PubMed ID: 28053526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell microenvironment stimuli-responsive controlled-release delivery systems based on mesoporous silica nanoparticles.
    Zhu CL; Wang XW; Lin ZZ; Xie ZH; Wang XR
    J Food Drug Anal; 2014 Mar; 22(1):18-28. PubMed ID: 24673901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in mesoporous silica-based nanocarriers for co-delivery and combination therapy against cancer.
    Castillo RR; Colilla M; Vallet-Regí M
    Expert Opin Drug Deliv; 2017 Feb; 14(2):229-243. PubMed ID: 27402029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insights towards mesoporous silica nanoparticles as a technological platform for chemotherapeutic drugs delivery.
    Sábio RM; Meneguin AB; Ribeiro TC; Silva RR; Chorilli M
    Int J Pharm; 2019 Jun; 564():379-409. PubMed ID: 31028801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesoporous silica nanoparticles in drug delivery and biomedical applications.
    Wang Y; Zhao Q; Han N; Bai L; Li J; Liu J; Che E; Hu L; Zhang Q; Jiang T; Wang S
    Nanomedicine; 2015 Feb; 11(2):313-27. PubMed ID: 25461284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesoporous silica nanoparticles decorated with polycationic dendrimers for infection treatment.
    González B; Colilla M; Díez J; Pedraza D; Guembe M; Izquierdo-Barba I; Vallet-Regí M
    Acta Biomater; 2018 Mar; 68():261-271. PubMed ID: 29307796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesoporous silica nanoparticles for intracellular controlled drug delivery.
    Vivero-Escoto JL; Slowing II; Trewyn BG; Lin VS
    Small; 2010 Sep; 6(18):1952-67. PubMed ID: 20690133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.